Bristol Myers Squibb (BMY) Tax Provisions (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Tax Provisions for 18 consecutive years, with $770.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Tax Provisions rose 67.39% year-over-year to $770.0 million in Q2 2026; TTM through Jun 2026 was $2.6 billion, a 72.27% increase from a year earlier, with the FY2025 full-year figure at $2.3 billion, up 310.11% from the prior year.
• Tax Provisions was $770.0 million for Q2 2026 at Bristol Myers Squibb, up from $561.0 million in the prior quarter.
• Over five years, Tax Provisions peaked at $919.0 million in Q3 2025 and troughed at -$398.0 million in Q2 2024.
• A 5-year average of $329.2 million and a median of $432.0 million in 2022 frame the typical range for Tax Provisions.
• Across the five-year window, Tax Provisions plunged 141.21% in 2023 and jumped 287.88% in 2025, its largest moves.
• Over 5 years, Tax Provisions stood at -$166.0 million in 2022, then jumped by 46.99% to -$88.0 million in 2023, then jumped by 212.5% to $99.0 million in 2024, then jumped by 287.88% to $384.0 million in 2025, then soared by 100.52% to $770.0 million in 2026.
• The last three Tax Provisions figures came in at $770.0 million (Q2 2026), $561.0 million (Q1 2026), and $384.0 million (Q4 2025), per Business Quant data.